IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

MARY KATHERINE LEVINGE COLLINS

Application No. Not Yet Assigned

Filed: Concurrently Herewith

For: EXPRESSION SYSTEMS

PRELIMINARY AMENDMENT

Before calculation of the filing fee, please amend the claims as follows:

Cancel claims 4-28.

Please add the following new claims:

A recombinant expression vector according to claim, wherein the vector is a human complement-resistant retroviral vector.

3.1. A recombinant expression vector according to claim 1 wherein the gene of interest is included as part of a viral packaging construct.

A recombinant expression vector according to claim 1, wherein the number of nucleotides in the space between the stop codon of the gene of interest and the start codon of the selectable marker is in the range of from 20 to 200 nucleotides.

A recombinant expression vector according to claim 32, wherein the number of nucleotides in the space between the stop codon of the gene of interest and the start codon of the selectable marker is in the range of from 60 to 80 nucleotides.

34. A process for producing a cell line in which a

W